Analysts Goldman Sachs initiate coverage of Hemab Therapeutics (HEMA) with Buy rating and $36 target price, citing potential for unique bleeding disorder treatment
Hemab Therapeutics is positioned for significant growth following its IPO, driven by its development of unique treatments for rare bleeding disorders, as highlighted by Goldman Sachs' bullish outlook.